Fundamental analysis AKBA (Akebia Therapeutics Inc)

Updated on 06/08/2026

We analyzed Akebia Therapeutics stock against the 10 quality criteria of Lubin Investment. The company gets a quality score of 5/10, meaning medium quality, and a P/FCF valuation multiple of 5.4×.

Sector: Drug Manufacturers - Specialty & Generic. Listing: US. Current price: 0.91 USD.

Lubin scoring methodology

Akebia Therapeutics Inc (AKBA)'s score is calculated automatically from 10 objective financial criteria, with no human intervention or opinion. Each criterion is validated (YES / PARTIAL / NO) based on thresholds drawn from the financial literature (Warren Buffett, Bettin-Mauboussin, Aswath Damodaran). The final score is the sum of validations.

The 10 quantitative criteria analyzed

1. Profitable: positive net margin
2. Growing revenue: revenue growing > 10%/year over 5 years
3. Growing earnings per share: FCF per share adjusted for stock-based compensation, > 10%/year over 5 years
4. Share count under control: stable or declining (net buybacks = value creation for shareholders)
5. Cash profitability: free cash flow margin > 10% of revenue
6. Expanding margins: operating margin widens over 5 years (operating leverage)
7. Return on invested capital: Bettin-Mauboussin Cash ROCE > 15% per year
8. Debt under control: net debt repayable in less than 3 years of free cash flow
9. Earnings converted to cash: free cash flow exceeds accounting net income
10. Net collection period: short or negative cash conversion cycle

Frequently asked questions

Is Akebia Therapeutics a quality stock?

Akebia Therapeutics gets a quality score of 5/10 (medium quality), calculated over the 10 Lubin Investment criteria: profitability, revenue and free cash flow growth, share buybacks, margins, debt and return on capital.

How is Akebia Therapeutics's score calculated?

The score is the total of validated criteria (YES / PARTIAL / NO) using thresholds drawn from the financial literature (Warren Buffett, Mauboussin, Aswath Damodaran), automatically and with no human opinion.

What is Akebia Therapeutics's P/FCF?

The price-to-free-cash-flow (P/FCF) multiple of Akebia Therapeutics stock is 5.4×. At Lubin Investment, valuation is judged separately from quality.

Where to see Akebia Therapeutics's full analysis?

The full interactive analysis (10-criteria detail, history, P/FCF valuation, sector comparisons) is available at https://lubin-investment.com/analyse/AKBA?lng=en.

Other stocks in the Drug Manufacturers Specialty & Generic sector

• Collegium Pharmaceutical (COLL) — score 10/10, P/FCF 3.8×
• Lantheus Holdings (LNTH) — score 9/10, P/FCF 20.1×
• Sun Pharmaceutical Industries (SUNPHARMA.NS) — score 9/10, P/FCF 48.6×
• Neurocrine Biosciences (NBIX) — score 9/10, P/FCF 27.1×
• Fagron (FAGR.BR) — score 9/10, P/FCF 14.0×

Go further

👉 See the full interactive analysis of AKBA

Other resources : Detailed methodology · All stocks in the Drug Manufacturers Specialty & Generic sector · Stocks rated 10 out of 10 · Top quality companies · Lubin Investment pricing.